ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: 3 Hochhaus Hochhaus A A Saglio Saglio G G Larson Larson RA RA Kim Kim DW DW Etienne Etienne G G Rosti Rosti G G Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase Blood.